Navigation Links
Arena Pharmaceuticals Announces First Quarter 2009 Financial Results
Date:5/11/2009

mon stock to Azimuth at a pre-negotiated discount to the market price.

  • Received net proceeds of $14.6 million as reimbursement for improvements made to one of Arena's facilities.

  • Announced the completion of a positive randomized, double-blind, placebo-controlled Phase 1 program and the initiation of a Phase 2 clinical trial of a second generation oral niacin receptor agonist intended for the treatment of atherosclerosis in Arena's partnership with Merck.

Scheduled Earnings Call

Arena will host both a conference call and webcast to discuss the first quarter 2009 financial results and to provide a business and financial update today, Monday, May 11, 2009, at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time). Jack Lief, President and Chief Executive Officer and Robert E. Hoffman, Vice President, Finance and Chief Financial Officer will host the conference call.

The conference call may be accessed by dialing 877.857.6151 for domestic callers and 719.325.4806 for international callers. Please specify to the operator that you would like to join the "Arena Pharmaceuticals First Quarter 2009 Earnings Call." The conference call will be webcast live under the investor relations section of Arena's website at www.arenapharm.com, and will be archived there for 30 days following the call. Please connect to Arena's website several minutes prior to the start of the broadcast to ensure adequate time for any software download that may be necessary.

Upcoming Corporate Presentations

Arena is planning to present at upcoming investment and industry conferences, including:

  • The 34th Annual Deutsche Bank Health Care Confer
    '/>"/>

SOURCE Arena Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Arena Pharmaceuticals to Host Business and Financial Update Conference Call and Webcast on Monday, May 11, 2009
2. Arena Pharmaceuticals Obtains Equity Financing Commitment of Up to $50 Million
3. Arena Pharmaceuticals to Present at the 27th Annual J.P. Morgan Healthcare Conference
4. Arena Pharmaceuticals to Present at the Oppenheimer 19th Annual Healthcare Conference
5. Arena Pharmaceuticals to Report Third Quarter 2008 Financial Results and to Host Conference Call and Webcast on Thursday, October 30, 2008
6. Arena Pharmaceuticals to Present at the BIOCOM Investor Conference
7. Arena Pharmaceuticals to Present at the Natixis Bleichroeder Second Annual Hidden Gems Conference
8. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
9. Arena Pharmaceuticals Announces Second Quarter 2008 Financial Results and Recent and Second Quarter Highlights
10. Arena Pharmaceuticals to Report Second Quarter 2008 Financial Results and to Host Conference Call and Webcast on Tuesday, August 5, 2008
11. Arena Pharmaceuticals to Present at the Seventh Annual Needham & Company, LLC Biotechnology and Medical Technology Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... 29, 2015 US-Australian drug discovery company, Novogen ... it is committed to progressing its ground-breaking technology platforms ... and to ensure the Company delivers the best value ... Iain Ross , said the Company currently had an ... programs, discovery programs and academic partnerships and initiatives, and ...
(Date:7/29/2015)... July 29, 2015 /PRNewswire/ - BioAmber Inc. (NYSE: BIOA ... Company,s Chief Financial Officer has resigned.  The Company has ... Officer who retired in December 2014, as full time ... permanent successor.     Andy Ashworth began ... ensure a smooth transition.  Andy was the Company,s CFO ...
(Date:7/29/2015)... FRANCISCO , July 29, 2015  AsureQuality ... mobile molecular testing for applications in food and ... hand-held, battery powered real-time PCR device, the Freedom4. ... farm right through to the supermarket shelf for ... This includes involvement in animal disease control and ...
(Date:7/29/2015)... DUBLIN , July 29, 2015 ... ) has announced the addition of the ... to their offering. The Global Biosimilars ... study of the rapidly growing biosimilars market. With ... industry striving to minimize costs, biosimilars are being ...
Breaking Biology Technology:Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 2Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 3Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 4Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 5Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 6Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 7Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 8Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 9Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 10BioAmber Announces Change in Chief Financial Officer 2BioAmber Announces Change in Chief Financial Officer 3AsureQuality and Ubiquitome Partner on Applications for Mobile Molecular Food Safety Testing 2Global Biosimilars Market to 2025: Monoclonal Antibodies (mAbs), Insulin, Interferons, G-CSF/ GM-CSF, Erythropoietins and Others 2Global Biosimilars Market to 2025: Monoclonal Antibodies (mAbs), Insulin, Interferons, G-CSF/ GM-CSF, Erythropoietins and Others 3
... WA, May 1 /PRNewswire-FirstCall/ - Oncothyreon Inc. ... filed an investigational new,drug (IND) application with ... a small molecule phosphatidylinositol-3-kinase (PI-3-kinase),inhibitor for the ... plans to initiate a Phase 1 clinical ...
... produced tiny liquid crystal devices with electrodes made from ... computer and TV displays based on this technology. , ... Dr Kostya Novoselov and colleagues from The School of ... report on the use of graphene as a transparent ...
... SAN DIEGO, April 30 Anadys Pharmaceuticals,Inc. (Nasdaq: ... improving,patient care by developing novel medicines in the ... financial results and highlights for the first,quarter ended ... in both of our development programs,during the first ...
Cached Biology Technology:Oncothyreon files investigational new drug application for PX-866 oncology compound 2Oncothyreon files investigational new drug application for PX-866 oncology compound 3Graphene-based gadgets may be just years away 2Anadys Pharmaceuticals Reports First Quarter 2008 Financial Results and Highlights 2Anadys Pharmaceuticals Reports First Quarter 2008 Financial Results and Highlights 3Anadys Pharmaceuticals Reports First Quarter 2008 Financial Results and Highlights 4Anadys Pharmaceuticals Reports First Quarter 2008 Financial Results and Highlights 5Anadys Pharmaceuticals Reports First Quarter 2008 Financial Results and Highlights 6Anadys Pharmaceuticals Reports First Quarter 2008 Financial Results and Highlights 7Anadys Pharmaceuticals Reports First Quarter 2008 Financial Results and Highlights 8
(Date:7/13/2015)... JOSE, Calif. , July 13, 2015 /PRNewswire/ ... leading developer of human interface solutions, today announced ... generation touch and display driver integration (TDDI) product ... is the first to combine Synaptics , ... with proven display driver technology developed in the ...
(Date:7/9/2015)... , July 9, 2015  Synaptics Inc. (NASDAQ: ... announced today that it will report financial results for ... July 30, 2015 after the close of market. The ... and investors at 2:00 p.m. PT (5:00 p.m. ET), ... To participate on the live call, analysts and ...
(Date:7/9/2015)... 2015  Unchained Labs just can,t get enough ... Avid Nano. Avid Nano designs, develops and manufactures ... Also today, Unchained Labs UNcaged the ... use protein sizing system. The pUNk is a ... size, size distribution, aggregation population and molecular weight. ...
Breaking Biology News(10 mins):Synaptics Announces Sampling of Second Generation TDDI Solutions 2Synaptics Announces Sampling of Second Generation TDDI Solutions 3Synaptics to Report Fourth Quarter, Fiscal Year 2015 Results on July 30 2Unchained Labs just can't get enough, acquires Avid Nano, rocks out the new pUNk! 2
... their genes, yet they differ dramatically in many ways---their walk, ... and language, for example. , Scientists would like to ... from the University of Michigan shows how one process---gene loss---may ... by associate professor of ecology and evolutionary biology Jianzhi Zhang, ...
... connected to the University of Antwerp are the first to ... is a major risk factor for Alzheimer's disease. Amyloid protein ... the senile plaques in the brains of patients. The new ... that is produced, the younger the dementia patient is. ...
... have found that the curry spice turmeric holds ... prostate cancer, particularly when combined with certain vegetables. ... curcumin, along with phenethyl isothiocyanate (PEITC), a naturally ... vegetables that includes watercress, cabbage, winter cress, broccoli, ...
Cached Biology News:Less is more, gene study shows 2Less is more, gene study shows 3Researchers discover a new genetic cause of Alzheimer's disease 2Curry and cauliflower could halt prostate cancer 2
... StabilZyme NOBLE BSA-Free Stabilizer is ... SELECT Stabilizer. It is an ... chemicals in a MOPS buffer (3-(N-Morpholino) ... and contains a combination of 0.02% ...
Mouse monoclonal antibody to PARK2 - Parkinson disease (autosomal recessive, juvenile) 2, parkin...
These 96-well 0.2 ml thin-wall PCR plate caps are caps that are used to seal 96-well, 0.2 ml thin-wall PCR plates. Supplied as 300 caps....
Rabbit polyclonal antibody to NMDA NR2B [Tyr1336]...
Biology Products: